<DOC>
	<DOCNO>NCT01637454</DOCNO>
	<brief_summary>Various vasoconstrictor show promising result management type 1 hepatorenal syndrome ( HRS ) . However , study vasopressor management type 2 HRS . Terlipressin use commonly ; however costly available country . In present study , investigator evaluate safety efficacy terlipressin noradrenaline treatment type 2 HRS</brief_summary>
	<brief_title>TYPE 2 HEPATORENAL SYNDROME</brief_title>
	<detailed_description />
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<criteria>1 . Cirrhosis ascites serum creatinine 1.5 mg/dl less 2.5 mg/dl 2 . Absence shock , fluid loss treatment nephrotoxic drug 3 . No improvement renal function follow diuretic withdrawal plasma volume expansion 4 . No ultrasound evidence renal parenchymal disease obstructive uropathy 5.Absence proteinuria 500 mg/24 hour 1 . Patients history coronary artery disease 2 . Cardiomyopathy 3 . Ventricular arrhythmia 4 . Obstructive arterial disease limb</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>noradrenaline terlipressin type 2 HRS</keyword>
</DOC>